Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.

Kim MY, Guerra MM, Kaplowitz E, Laskin CA, Petri M, Branch DW, Lockshin MD, Sammaritano LR, Merrill JT, Porter TF, Sawitzke A, Lynch AM, Buyon JP, Salmon JE.

Ann Rheum Dis. 2018 Apr;77(4):549-555. doi: 10.1136/annrheumdis-2017-212224. Epub 2018 Jan 25.

PMID:
29371202
2.

Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus.

Buyon JP, Kim MY, Guerra MM, Lu S, Reeves E, Petri M, Laskin CA, Lockshin MD, Sammaritano LR, Branch DW, Porter TF, Sawitzke A, Merrill JT, Stephenson MD, Cohn E, Salmon JE.

Clin J Am Soc Nephrol. 2017 Jun 7;12(6):940-946. doi: 10.2215/CJN.11431116. Epub 2017 Apr 11.

3.

The Importance of an Evidence-based Workup for Recurrent Pregnancy Loss.

Gibbins KJ, Porter TF.

Clin Obstet Gynecol. 2016 Sep;59(3):456-63. doi: 10.1097/GRF.0000000000000219. Review.

PMID:
27455202
4.

Foreword.

Silver RM, Branch DW, Porter TF.

Clin Obstet Gynecol. 2016 Sep;59(3):455. doi: 10.1097/GRF.0000000000000220. No abstract available.

PMID:
27403583
5.

Patient Counseling and Preferences for Elective Repeat Cesarean Delivery.

Folsom S, Esplin MS, Edmunds S, Metz TD, Jackson GM, Porter TF, Varner MW.

AJP Rep. 2016 Apr;6(2):e226-31. doi: 10.1055/s-0036-1584529.

6.

Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes.

Yelnik CM, Porter TF, Branch DW, Laskin CA, Merrill JT, Guerra MM, Lockshin MD, Buyon JP, Petri M, Sammaritano LR, Stephenson MD, Kim MY, Salmon JE.

Arthritis Rheumatol. 2016 Aug;68(8):1964-9. doi: 10.1002/art.39668.

7.

Detection and confirmation of serum lipid biomarkers for preeclampsia using direct infusion mass spectrometry.

Anand S, Young S, Esplin MS, Peaden B, Tolley HD, Porter TF, Varner MW, D'Alton ME, Jackson BJ, Graves SW.

J Lipid Res. 2016 Apr;57(4):687-96. doi: 10.1194/jlr.P064451. Epub 2016 Feb 18.

8.

Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results.

Yelnik CM, Laskin CA, Porter TF, Branch DW, Buyon JP, Guerra MM, Lockshin MD, Petri M, Merrill JT, Sammaritano LR, Kim MY, Salmon JE.

Lupus Sci Med. 2016 Jan 12;3(1):e000131. doi: 10.1136/lupus-2015-000131. eCollection 2016.

9.

Tocolysis for Women With Early Spontaneous Preterm Labor and Advanced Cervical Dilation.

Manuck TA, Herrera CA, Korgenski EK, Jackson M, Stoddard GJ, Porter TF, Varner MW.

Obstet Gynecol. 2015 Nov;126(5):954-61. doi: 10.1097/AOG.0000000000001095.

10.

Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.

Kim MY, Buyon JP, Guerra MM, Rana S, Zhang D, Laskin CA, Petri M, Lockshin MD, Sammaritano LR, Branch DW, Porter TF, Merrill JT, Stephenson MD, Gao Q, Karumanchi SA, Salmon JE.

Am J Obstet Gynecol. 2016 Jan;214(1):108.e1-108.e14. doi: 10.1016/j.ajog.2015.09.066. Epub 2015 Sep 29.

11.

Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study.

Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, Sammaritano L, Branch DW, Porter TF, Sawitzke A, Merrill JT, Stephenson MD, Cohn E, Garabet L, Salmon JE.

Ann Intern Med. 2015 Aug 4;163(3):153-63. doi: 10.7326/M14-2235.

12.

Serum biomarkers predictive of pre-eclampsia.

Anand S, Bench Alvarez TM, Johnson WE, Esplin MS, Merrell K, Porter TF, Graves SW.

Biomark Med. 2015;9(6):563-75. doi: 10.2217/bmm.15.21.

PMID:
26079961
13.

Maternal and fetal morbidity associated with uterine rupture of the unscarred uterus.

Gibbins KJ, Weber T, Holmgren CM, Porter TF, Varner MW, Manuck TA.

Am J Obstet Gynecol. 2015 Sep;213(3):382.e1-6. doi: 10.1016/j.ajog.2015.05.048. Epub 2015 May 28.

PMID:
26026917
14.

Limited evidence for diagnosing and treating "non-criteria obstetric antiphospholipid syndrome".

Ramires de Jesús G, Levy RA, Porter TF, Branch DW.

Thromb Haemost. 2015 Aug 31;114(3):651-2. doi: 10.1160/TH15-02-0156. Epub 2015 May 7. No abstract available.

PMID:
25947158
15.

Prevalence of antiphospholipid antibodies and risk of subsequent adverse obstetric outcomes in women with prior pregnancy loss.

Bowman ZS, Wünsche V, Porter TF, Silver RM, Branch DW.

J Reprod Immunol. 2015 Feb;107:59-63. doi: 10.1016/j.jri.2014.09.052. Epub 2014 Oct 13.

PMID:
25453202
16.

Cervical length screening: a randomized trial assessing the impact on visit length and patient attitudes.

Romero ST, Holmgren CC, Feltovich H, Porter TF, Esplin MS.

J Ultrasound Med. 2014 Dec;33(12):2159-63. doi: 10.7863/ultra.33.12.2159.

PMID:
25425373
17.

Immunotherapy for recurrent miscarriage.

Wong LF, Porter TF, Scott JR.

Cochrane Database Syst Rev. 2014 Oct 21;(10):CD000112. doi: 10.1002/14651858.CD000112.pub3. Review.

PMID:
25331518
18.

Recurrent early pregnancy loss and antiphospholipid antibodies: where do we stand?

Wong LF, Porter TF, de Jesús GR.

Lupus. 2014 Oct;23(12):1226-8. doi: 10.1177/0961203314529170.

PMID:
25228711
19.

14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome.

de Jesus GR, Agmon-Levin N, Andrade CA, Andreoli L, Chighizola CB, Porter TF, Salmon J, Silver RM, Tincani A, Branch DW.

Autoimmun Rev. 2014 Aug;13(8):795-813. doi: 10.1016/j.autrev.2014.02.003. Epub 2014 Mar 17. Review.

PMID:
24650941
20.

A risk stratification model to predict adverse neonatal outcome in labor.

Holmgren CM, Esplin MS, Jackson M, Porter TF, Henry E, Horne BD, Varner MW.

J Perinatol. 2013 Dec;33(12):914-8. doi: 10.1038/jp.2013.64. Epub 2013 Oct 24.

PMID:
24157496
21.

Uterine rupture with attempted vaginal birth after cesarean delivery: decision-to-delivery time and neonatal outcome.

Holmgren C, Scott JR, Porter TF, Esplin MS, Bardsley T.

Obstet Gynecol. 2012 Apr;119(4):725-31. doi: 10.1097/AOG.0b013e318249a1d7.

PMID:
22433335
22.

Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.

Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, Petri M, Porter TF, Sammaritano L, Stephenson MD, Buyon J, Salmon JE.

Arthritis Rheum. 2012 Jul;64(7):2311-8. doi: 10.1002/art.34402.

23.

Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy.

Horne BD, Rasmusson KD, Alharethi R, Budge D, Brunisholz KD, Metz T, Carlquist JF, Connolly JJ, Porter TF, Lappé DL, Muhlestein JB, Silver R, Stehlik J, Park JJ, May HT, Bair TL, Anderson JL, Renlund DG, Kfoury AG.

Circ Cardiovasc Genet. 2011 Aug 1;4(4):359-66. doi: 10.1161/CIRCGENETICS.110.959205. Epub 2011 Jun 10.

PMID:
21665988
24.

Pregnancy outcomes in a recurrent preterm birth prevention clinic.

Manuck TA, Henry E, Gibson J, Varner MW, Porter TF, Jackson GM, Esplin MS.

Am J Obstet Gynecol. 2011 Apr;204(4):320.e1-6. doi: 10.1016/j.ajog.2011.01.011. Epub 2011 Feb 23.

PMID:
21345407
25.

Chemical mediators of inflammation and resolution in post-operative abdominal aortic aneurysm patients.

Pillai PS, Leeson S, Porter TF, Owens CD, Kim JM, Conte MS, Serhan CN, Gelman S.

Inflammation. 2012 Feb;35(1):98-113. doi: 10.1007/s10753-011-9294-8. Erratum in: Inflammation. 2012 Feb;35(1):397-8.

26.

Thyroperoxidase and thyroglobulin antibodies in early pregnancy and placental abruption.

Haddow JE, McClain MR, Palomaki GE, Neveux LM, Lambert-Messerlian G, Canick JA, Malone FD, Porter TF, Nyberg DA, Bernstein PS, D'Alton ME; First and Second Trimester Risk of Aneuploidy (FaSTER) Research Consortium.

Obstet Gynecol. 2011 Feb;117(2 Pt 1):287-92. doi: 10.1097/AOG.0b013e31820513d9.

PMID:
21252741
27.

Vascular endothelial growth factor-A gene polymorphisms in women with recurrent pregnancy loss.

Eller AG, Branch DW, Nelson L, Porter TF, Silver RM.

J Reprod Immunol. 2011 Jan;88(1):48-52. doi: 10.1016/j.jri.2010.06.159. Epub 2010 Oct 24.

PMID:
20977975
28.

Idiopathic recurrent pregnancy loss recurs at similar gestational ages.

Heuser C, Dalton J, Macpherson C, Branch DW, Porter TF, Silver RM.

Am J Obstet Gynecol. 2010 Oct;203(4):343.e1-5. doi: 10.1016/j.ajog.2010.05.010. Epub 2010 Jul 1.

PMID:
20579956
29.

Thyroperoxidase and thyroglobulin antibodies in early pregnancy and preterm delivery.

Haddow JE, Cleary-Goldman J, McClain MR, Palomaki GE, Neveux LM, Lambert-Messerlian G, Canick JA, Malone FD, Porter TF, Nyberg DA, Bernstein PS, D'Alton ME; First- and Second-Trimester Risk of Aneuploidy (FaSTER) Research Consortium.

Obstet Gynecol. 2010 Jul;116(1):58-62. doi: 10.1097/AOG.0b013e3181e10b30.

PMID:
20567168
30.

Obstetric antiphospholipid syndrome: current uncertainties should guide our way.

Branch DW, Silver RM, Porter TF.

Lupus. 2010 Apr;19(4):446-52. doi: 10.1177/0961203310361490.

PMID:
20353986
31.

Small-molecule screen identifies reactive oxygen species as key regulators of neutrophil chemotaxis.

Hattori H, Subramanian KK, Sakai J, Jia Y, Li Y, Porter TF, Loison F, Sarraj B, Kasorn A, Jo H, Blanchard C, Zirkle D, McDonald D, Pai SY, Serhan CN, Luo HR.

Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3546-51. doi: 10.1073/pnas.0914351107. Epub 2010 Feb 8.

32.

Role of second-trimester genetic sonography after Down syndrome screening.

Aagaard-Tillery KM, Malone FD, Nyberg DA, Porter TF, Cuckle HS, Fuchs K, Sullivan L, Comstock CH, Saade GR, Eddleman K, Gross S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Bianchi DW, D'Alton ME; First and Second Trimester Evaluation of Risk Research Consortium.

Obstet Gynecol. 2009 Dec;114(6):1189-96. doi: 10.1097/AOG.0b013e3181c15064.

33.

Resolvin D1 controls inflammation initiated by glutathione-lipid conjugates formed during oxidative stress.

Spite M, Summers L, Porter TF, Srivastava S, Bhatnagar A, Serhan CN.

Br J Pharmacol. 2009 Oct;158(4):1062-73. doi: 10.1111/j.1476-5381.2009.00234.x. Epub 2009 May 5.

34.

Optimal management strategies for placenta accreta.

Eller AG, Porter TF, Soisson P, Silver RM.

BJOG. 2009 Apr;116(5):648-54. doi: 10.1111/j.1471-0528.2008.02037.x. Epub 2009 Feb 4.

35.

Thromboprophylaxis and pregnancy outcomes in asymptomatic women with inherited thrombophilias.

Warren JE, Simonsen SE, Branch DW, Porter TF, Silver RM.

Am J Obstet Gynecol. 2009 Mar;200(3):281.e1-5. doi: 10.1016/j.ajog.2008.10.021. Epub 2008 Dec 27.

PMID:
19114274
36.

Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions.

Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M.

J Exp Med. 2009 Jan 16;206(1):15-23. doi: 10.1084/jem.20081880. Epub 2008 Dec 22.

37.

Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution.

Kasuga K, Yang R, Porter TF, Agrawal N, Petasis NA, Irimia D, Toner M, Serhan CN.

J Immunol. 2008 Dec 15;181(12):8677-87.

38.

Down syndrome serum screening also identifies an increased risk for multicystic dysplastic kidney, two-vessel cord, and hydrocele.

Hoffman JD, Bianchi DW, Sullivan LM, Mackinnon BL, Collins J, Malone FD, Porter TF, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME.

Prenat Diagn. 2008 Dec;28(13):1204-8. doi: 10.1002/pd.2082.

39.

Maternal thyroid hypofunction and pregnancy outcome.

Cleary-Goldman J, Malone FD, Lambert-Messerlian G, Sullivan L, Canick J, Porter TF, Luthy D, Gross S, Bianchi DW, D'Alton ME.

Obstet Gynecol. 2008 Jul;112(1):85-92. doi: 10.1097/AOG.0b013e3181788dd7.

40.

First- and second-trimester thyroid hormone reference data in pregnant women: a FaSTER (First- and Second-Trimester Evaluation of Risk for aneuploidy) Research Consortium study.

Lambert-Messerlian G, McClain M, Haddow JE, Palomaki GE, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Bernstein P, D'Alton ME; FaSTER Research Consortium.

Am J Obstet Gynecol. 2008 Jul;199(1):62.e1-6. doi: 10.1016/j.ajog.2007.12.003. Erratum in: Am J Obstet Gynecol. 2008 Sep;199(3):326.

41.

Variability in thyroid-stimulating hormone suppression by human chorionic [corrected] gonadotropin during early pregnancy.

Haddow JE, McClain MR, Lambert-Messerlian G, Palomaki GE, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Bernstein P, D'Alton ME; First and Second Trimester Evaluation of Risk for Fetal Aneuploidy Research Consortium.

J Clin Endocrinol Metab. 2008 Sep;93(9):3341-7. doi: 10.1210/jc.2008-0568. Epub 2008 Jun 10. Erratum in: J Clin Endocrinol Metab. 2008 Nov;93(11):4552.

42.

Sequential first- and second-trimester TSH, free thyroxine, and thyroid antibody measurements in women with known hypothyroidism: a FaSTER trial study.

McClain MR, Lambert-Messerlian G, Haddow JE, Palomaki GE, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Bernstein P, D'Alton ME; FaSTER Research Consortium.

Am J Obstet Gynecol. 2008 Aug;199(2):129.e1-6. doi: 10.1016/j.ajog.2008.02.036. Epub 2008 Apr 29.

PMID:
18448078
43.

Resolvin E1 metabolome in local inactivation during inflammation-resolution.

Hong S, Porter TF, Lu Y, Oh SF, Pillai PS, Serhan CN.

J Immunol. 2008 Mar 1;180(5):3512-9.

44.

Contingent screening for Down syndrome--results from the FaSTER trial.

Cuckle HS, Malone FD, Wright D, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Ferreira JC, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, D'Alton ME.

Prenat Diagn. 2008 Feb;28(2):89-94. doi: 10.1002/pd.1913.

PMID:
18236423
45.

In utero tobacco exposure is associated with modified effects of maternal factors on fetal growth.

Aagaard-Tillery KM, Porter TF, Lane RH, Varner MW, Lacoursiere DY.

Am J Obstet Gynecol. 2008 Jan;198(1):66.e1-6. doi: 10.1016/j.ajog.2007.06.078.

PMID:
18166310
46.

Hyperemesis in pregnancy: an evaluation of treatment strategies with maternal and neonatal outcomes.

Holmgren C, Aagaard-Tillery KM, Silver RM, Porter TF, Varner M.

Am J Obstet Gynecol. 2008 Jan;198(1):56.e1-4. doi: 10.1016/j.ajog.2007.06.004.

PMID:
18166306
47.

First- and second-trimester screening: detection of aneuploidies other than Down syndrome.

Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Tripp T, Bianchi DW, D'Alton ME; First and Second Trimester Evaluation of Risk (FASTER) Research Consortium.

Obstet Gynecol. 2007 Sep;110(3):651-7.

PMID:
17766613
48.

Collagen 1Alpha1 and transforming growth factor-beta polymorphisms in women with cervical insufficiency.

Warren JE, Silver RM, Dalton J, Nelson LT, Branch DW, Porter TF.

Obstet Gynecol. 2007 Sep;110(3):619-24.

PMID:
17766609
49.

The contribution of birth defects to preterm birth and low birth weight.

Dolan SM, Gross SJ, Merkatz IR, Faber V, Sullivan LM, Malone FD, Porter TF, Nyberg DA, Comstock CH, Hankins GD, Eddleman K, Dugoff L, Craigo SD, Timor-Tritsch I, Carr SR, Wolfe HM, Bianchi DW, D'Alton ME.

Obstet Gynecol. 2007 Aug;110(2 Pt 1):318-24.

PMID:
17666606
50.

Pregnancy loss rates after midtrimester amniocentesis.

Eddleman KA, Malone FD, Sullivan L, Dukes K, Berkowitz RL, Kharbutli Y, Porter TF, Luthy DA, Comstock CH, Saade GR, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME.

Obstet Gynecol. 2006 Nov;108(5):1067-72.

PMID:
17077226

Supplemental Content

Loading ...
Support Center